Related by context. All words. (Click for frequent words.) 76 Prostate Lung Colorectal 75 Multicenter Automatic Defibrillator Implantation 74 Ovarian Cancer Screening 73 PLCO 71 National Emphysema Treatment 71 Digital Mammographic Imaging 71 multicenter randomized controlled 69 CALERIE 69 Screening Trial DMIST 68 ACCORD Lipid 68 Cancer Prevention ATBC 68 Carotid Revascularization Endarterectomy vs. 67 PCPT 67 HYVET 67 WHEL 66 CAMMS# 66 Spine Patient Outcomes 66 Trial PCPT 66 multicenter randomized clinical 66 ONTARGET 66 Cholesterol Levels SPARCL 66 GISSI 66 Ovarian PLCO Cancer 66 BCIRG 65 Screening Trial 65 VADT 65 retrospective cohort 65 Lung Screening 65 Aggressive Reduction 65 Stenting Trial CREST 65 CALGB 65 Intervention Trial GAIT 65 Lung Cancer Screening 65 ExTRACT TIMI 65 Randomized Phase II 65 subanalysis 65 ALLHAT 65 RE LY ® 65 Ocular Hypertension Treatment 65 Glucosamine Chondroitin Arthritis 64 STRIDE PD 64 AVADO 64 Clinical Antipsychotic Trials 64 BARI 2D 64 Trial NLST 64 ONTARGET R 64 ToGA 64 TRITON TIMI 64 RE LY 64 ACRIN 64 NCCTG N# 64 Wisconsin Sleep Cohort 64 CLARITY TIMI 64 EURIDIS 64 MADIT II 64 randomized controlled clinical 64 AIM HIGH 64 Intervention Effectiveness 63 WHI Dietary Modification 63 Framingham Offspring Study 63 placebo controlled clinical 63 Polyp Prevention Trial 63 ADMIRE HF 63 HCV SPRINT 63 Health Initiative Observational 63 Multicenter AIDS 63 Cardiovascular Risk 63 PREVENT IV 63 NSABP B 63 Gynecologic Oncology Group 63 Multicenter Randomized 63 Alpha Tocopherol Beta Carotene 63 EVEREST II 63 multicenter placebo controlled 63 INTERHEART study 63 Randomized controlled 63 Phase III AFFIRM 63 Randomized Phase III 63 Prostate AdenoCarcinoma Treatment 63 Swedish Mammography Cohort 63 multicentre randomized 62 ENESTnd 62 CARE HF 62 BRIM3 62 ERSPC 62 Intervention Effectiveness CATIE 62 SPIRIT FIRST 62 double blinded randomized 62 ELCAP 62 Randomized Controlled 62 AVOREN 62 Evaluation WISE 62 SPARCL 62 LUX Lung 62 iPrEx 62 Osteoporotic Fractures 62 DMIST 62 longitudinal cohort study 62 Intervention Trial 62 randomized clinical 61 LUMINATE 61 Health Initiative WHI 61 prospective observational cohort 61 NHANES III 61 HPTN 61 Randomised 61 Delcath Phase III 61 Edge STudy 61 undergone radical prostatectomy 61 Sibutramine Cardiovascular Outcomes 61 galiximab 61 Adenoma Prevention 61 SPIRIT IV 61 prospectively defined 61 ENDEAVOR IV 61 NSABP 61 NEVO RES 61 NCT# ClinicalTrials.gov 61 Women Ischemia Syndrome 61 SCD HeFT 61 selenium supplementation 61 Val HeFT 61 Multicenter Phase 61 TAXUS ATLAS 61 Subgroup analysis 60 Randomized Evaluation 60 Phase Ib clinical 60 ACTIVE W 60 landmark ATHENA 60 Netherlands Cohort Study 60 Nymox NX 60 CAPRIE 60 Kaplan Meier analysis 60 Sorafenib HCC Assessment 60 relapsed MM 60 Diabetes ACCORD 60 RTOG 60 SWOG 60 Lipid Lowering Treatment 60 DAPT 60 prospective observational 60 prospective randomized placebo 60 multicentre randomized controlled 60 substudy 60 multicenter clinical 60 randomized multicenter 60 ABCSG 60 BRIM2 60 Dietary Modification Trial 60 TG MV 60 SPIRIT III 60 Gastric Cancer 60 ECASS 60 prospective multicenter 60 dutasteride 60 postmenopausal hormone therapy 60 Renal Cell Carcinoma RCC 60 HIVNET 60 SORT OUT III 60 prospective multicentre 60 ASCO GU 60 AVERROES 60 multicentre prospective 60 Kaplan Meier 60 ACCOMPLISH 60 PRoFESS 60 APPROVe 60 CARDIA 60 Phase III randomized 60 Celecoxib APC trial 60 endometrial hyperplasia 60 LibiGel Phase III 60 MADIT CRT 59 Colorectal Cancers 59 randomized Phase IIb 59 RE LY trial 59 HGPIN 59 HCV RESPOND 2 59 HORIZONS AMI 59 Phase III VISTA 59 Insulin Resistance Atherosclerosis 59 Folfox 59 ENDEAVOR III 59 adenoma recurrence 59 PERSEUS 59 CALGB # [002] 59 BR.# 59 CALGB # [001] 59 Nutrition EPIC 59 prostate cancer CaP 59 Therapeutic Arthritis 59 ARBITER 6 59 Communities ARIC study 59 Arch Surg 59 multicenter phase 59 APPRAISE 59 Dubbo Osteoporosis Epidemiology 59 underwent radical prostatectomy 59 Asthma Intervention 59 MADIT 59 Arimidex Tamoxifen Alone 59 ACUITY trial 59 trials RCTs 59 riociguat 59 ISAR REACT 59 Phase IIIb clinical 59 Prospective Randomized 59 GYTS 59 Baltimore Longitudinal Study 59 multicenter randomized 59 liver transplant recipients 59 beta carotene supplementation 59 advanced adenoma 59 Randomized Phase 59 Neuroepidemiology 59 randomized controlled trials RCTs 59 Raloxifene STAR 59 Atherosclerosis MESA 59 CARDIA study 59 renal cell carcinomas 59 HF ACTION 59 Randomized Clinical Trial 59 viral kinetic 59 Radiation Therapy Oncology 59 Placebo controlled 59 Multicenter 59 Meta analyzes 59 subgroup analyzes 59 European Randomized Study 59 Raloxifene Evaluation MORE 59 TAXUS IV 59 ENDEAVOR II 59 ClinicalTrials.gov 59 NHANES 59 retrospective cohort study 59 Cardiovascular Outcomes 59 specific antigen PSA 59 Phase III Pivotal 58 Platelet Inhibition 58 HIV HCV coinfected 58 ISEL 58 Clinical Outcomes Utilizing Revascularization 58 prospectively randomized 58 STEP BD 58 CATIE AD 58 prospective longitudinal 58 Pooled Analysis 58 tesmilifene 58 HeFT 58 PROactive study 58 NATRECOR R 58 Breast Density 58 Prospective Multicenter 58 placebo controlled randomized 58 ACOSOG Z# 58 iPrEx study 58 Uterine Cancer 58 ASTEROID 58 GnRH agonists 58 symptomatic BPH 58 phase III ACCLAIM 58 Cochrane Systematic Review 58 CHAMPION PCI 58 Professionals Follow 58 Prostate Cancer ERSPC 58 blind randomized controlled 58 Adjuvant Chemotherapy 58 RECORD1 58 Hepatotoxicity 58 REALITY Trial 58 ASSERT 58 multicenter multinational 58 HORIZONS AMI trial 58 EchoCRT 58 Reduce Cardiovascular 58 observational cohort 58 nonrandomized 58 Neoadjuvant 58 neoadjuvant 58 ENGAGE AF TIMI 58 PreCISe 58 Echocardiographic 58 phase IIIb 58 EMPHASIS HF trial 58 Arch Intern Med 58 Diabetes Interventions 58 TAXUS VI 58 ALSYMPCA 58 Nonalcoholic Fatty Liver Disease 58 Motesanib 58 Treat Parkinson Disease 58 Long Lesion 58 Thrombolysis 58 Prostate Cancer Outcomes 58 Degarelix 58 phase IIb clinical 58 Phase Ib II 58 SEER database 58 Pivotal Phase III 58 iniparib BSI 58 Atherosclerosis Risk 58 Young Adults CARDIA 58 PSA screening 58 Randomized Study 58 Randomised Badger Culling 58 Framingham Offspring 58 WHIMS 58 Randomized Double blind 58 placebo controlled Phase III 58 dietary questionnaires 57 Stent Thrombosis 57 randomized Phase III 57 Malignant Melanoma 57 breast cancer recurrences 57 RIO Lipids 57 prospective observational studies 57 Invasive Breast Cancer 57 flutamide 57 number NCT# ClinicalTrials.gov 57 registrational Phase 57 NO# [002] 57 placebo controlled trials 57 Stenting Trial 57 Carotid Endarterectomy 57 OPT CHF 57 observational studies 57 Septic Shock 57 CURRENT OASIS 7 57 Prospective Randomized Trial 57 Multi Ethnic Study 57 CHARM Added 57 RE MODEL 57 HOPE TOO 57 testosterone supplementation 57 prospective nonrandomized 57 AREDS 57 IMPROVE HF 57 Carotid Stenting 57 End Results SEER 57 Scandinavian Simvastatin Survival 57 ZACTIMA 57 pCR 57 multicenter randomized placebo controlled 57 meta regression 57 COU AA 57 Inflammatory Markers 57 Acute Decompensated Heart Failure 57 SIMPADICO 57 Prostate Cancers 57 clinico pathological 57 phase IIa clinical 57 Dialysis Outcomes 57 operable pancreatic cancer 57 Hepatocellular Carcinoma HCC 57 longitudinal observational study 57 AA Amyloidosis 57 atrasentan 57 colorectal adenoma 57 multicenter prospective 57 mammographic density 57 assessing T DM1 57 randomized controlled multicenter 57 mcg linaclotide 57 blinded randomized 57 PROSTVAC VF 57 randomized multicentre 57 recurrent venous thromboembolism 57 ARCALYST ® rilonacept 57 Common Toxicity Criteria 57 Glucosamine chondroitin Arthritis 57 logistic regression analyzes 57 olaparib 57 JAK Inhibitor 57 Cognitive Function 57 Antihypertensive 57 Estrogen Alone 57 Multicentre 57 Trandolapril 57 placebo controlled Phase 57 recurrent VTE 57 Phase IIIb 57 PLCO trial 57 SWiTCH 57 Postmenopausal Women 57 Secondary efficacy endpoints 57 Multicenter Trial 57 Placebo Controlled Trial 57 MADIT CRT trial 57 ongoing Phase 1b 57 cilostazol 57 intensive statin therapy 57 Hormone Refractory Prostate Cancer 57 CYPHER Stent 57 elevated CRP 57 folate supplementation 57 Complications Trial 57 randomized blinded 57 Liraglutide Effect 57 randomized multicenter Phase III 57 postmenopausal women 57 TARGIT 57 SABCS 57 metastatic HRPC 57 Prostate Cancer Screening 57 blinded randomized placebo controlled 57 AIR2 Trial 56 STEALTH C 56 Oral Fingolimod 56 randomized multicenter trial 56 MERLIN TIMI 56 Breast Cancer Risk 56 PRE SURGE 56 Surveillance Epidemiology 56 cutaneous melanoma 56 BZA CE 56 ROCKET AF 56 Acute Myocardial Infarction 56 Randomized Controlled Trials 56 prospective cohort 56 PROTECT AF 56 Canadian Multicentre Osteoporosis 56 Prostate Cancer Risk 56 Severe Asthma 56 Prostate Cancer Patients 56 Teriflunomide 56 rimonabant #mg 56 Coronary Artery Calcium 56 infantile colic 56 vismodegib 56 dysglycemia 56 anastrozole 56 PON1 activity 56 Adenomas 56 UKPDS 56 Infarct 56 Glioma 56 evaluable subjects 56 PIX# [002] 56 Sipuleucel T 56 CIN2 + 56 NICE SUGAR 56 Recurrent Stroke 56 Afatinib 56 Combination REOLYSIN R 56 postoperative mortality 56 Nord Trøndelag Health 56 Myocardial Infarction 56 pivotal bioequivalence 56 Refractory Angina 56 prospective randomized multicenter 56 Restenosis 56 Surgical Treatment 56 Xelox 56 meta analyzes 56 FDG PET 56 Group RTOG 56 T1DM 56 Ozarelix 56 exemestane 56 Diabetic Nephropathy 56 multicenter 56 Aortic Stenosis 56 Non inferiority 56 asymptomatic carotid stenosis 56 FOLPI 56 Malignant Glioma 56 quadrivalent HPV vaccine 56 Renal Cell Carcinoma 56 Apixaban 56 recurrent glioblastoma multiforme 56 STICH trial 56 VESTASYNC 56 MGd 56 ACCORD Eye 56 Prognostic Value 56 GISSI HF 56 nulliparous women 56 randomized controlled clinical trials 56 Scandinavian Cardiac Outcomes 56 Phase III Clinical Trials 56 Phase III HEAT 56 EUROCARE 56 PHPT 56 RCTs 56 QTc prolongation 56 underwent CABG 56 ENDEAVOR clinical 56 Acute Coronary Syndromes 56 Cytogenetic 56 MEND CABG 56 MAGE A3 ASCI 56 Pivotal Phase 56 HER2 expression 56 elevated ALT 56 BOLDER II 56 SYMMETRY trial 56 Therapeutic Effects 56 MELD scores 56 CAPRISA 56 randomized controlled trials 56 nonpregnant women 56 KRAS mutation 56 Acute Ischemic Stroke 56 randomized trials 56 #F FDG PET 56 TAXUS ARRIVE 56 masked placebo controlled 56 F FDG PET 56 AVAiL 56 Controlled Trial 56 Sustained Efficacy 56 Cardiotoxicity 56 Nutrition Examination Surveys 56 Metastatic Colorectal Cancer 56 Randomized Double Blind 56 multicenter randomized double 56 Early Lung Cancer 56 J Clin Endocrinol Metab 56 Patient Outcomes 56 J Clin Oncol 56 axitinib 56 Severe Sepsis 56 FAME Study 56 Medullary Thyroid Cancer 56 PRECiSE 56 CHAMPION PLATFORM 56 Observational studies 56 oral bisphosphonate 56 meta analysis 56 Celebrex celecoxib 56 homocysteine concentrations 56 colorectal cancer incidence 56 advanced adenomas 56 Cardiovascular Events 56 metastatic GIST 56 GAMMAGARD 56 ataluren 56 nab paclitaxel 56 Novartis Zometa 56 everolimus eluting stents 56 Phase III placebo controlled 56 definite stent thrombosis 56 Angiographic 55 Phase III Psoriasis 55 Nicotine Addiction 55 CaPSURE 55 prostate biopsies 55 fosbretabulin 55 Cohort Study MACS 55 multicenter trials 55 recurrent glioma 55 See CLINICAL PHARMACOLOGY 55 Hydroxyurea 55 CONQUER OB 55 EUS FNA 55 Cancer Incidence Mortality 55 TOHP 55 Bivalirudin 55 multicenter study 55 SYNTAX 55 NMIBC 55 androgen suppression 55 PCa 55 afatinib 55 colorectal bowel 55 pre menopausal 55 Prostate Disease 55 COSTAR II 55 tarenflurbil 55 hormone refractory metastatic prostate 55 Lung Injury 55 confirmatory clinical 55 Genotypes 55 ENDEAVOR IV clinical 55 Recurrent Breast Cancer 55 mycophenolate mofetil 55 blind multicenter 55 Postmenopausal 55 multicentre 55 KRAS status 55 Adjuvant Breast Cancer 55 placebo controlled studies 55 Lancet Oncology journal 55 Multiethnic Study 55 Hepatitis C Infection 55 Breast Cancer Recurrence 55 ORACLE MS 55 Enzastaurin 55 Phytotherapy Research 55 Phase III psoriasis 55 COPERNICUS 55 Pemetrexed 55 recurrent GBM 55 Benign Prostatic Hyperplasia 55 Investigator Initiated 55 Randomised Study 55 Advaxis Phase 55 Combination Treatment 55 histologically confirmed 55 Slone Epidemiology Center 55 Histopathological 55 DASISION 55 BRCA testing 55 blinded randomized controlled 55 Venous Thromboembolism 55 advanced neoplasia 55 randomized controlled 55 TMC# C# 55 neoadjuvant treatment 55 double blinded placebo 55 Overactive Bladder 55 Colposcopy 55 prostate cancer CRPC 55 NovoTTF 55 NCCTG 55 PSMA ADC 55 receiving SIMPONI 55 Estradiol 55 operable breast cancer 55 prostate cancer PCa 55 EORTC 55 mg BID dose 55 Pivotal Trial 55 mild gestational diabetes 55 FOLFOX4 55 Ischemic Stroke 55 Pharmacokinetic PK 55 endometriosis ovarian cysts 55 Colorectal Cancer Patients 55 nonmetastatic 55 Early Childhood Longitudinal Study 55 standard chemotherapy regimen 55 Advanced Melanoma 55 lipid lowering drugs 55 heFH 55 estrogen progestin therapy 55 Non Melanoma Skin 55 Phase IIA 55 DAPT Study 55 Hepatitis C Antiviral 55 XELOX 55 FIX HF 5 55 recurrent malignant glioma 55 Adjuvant chemotherapy 55 generalizability 55 conducted retrospective cohort 55 keloid scarring 55 multiple logistic regression 55 Subgroup analyzes 55 Childhood Asthma 55 Adjuvant 55 atherothrombotic disease 55 Breast Cancers 55 APEX AMI trial 55 metastatic hormone refractory 55 Multiple logistic regression 55 Study AREDS 55 Relapsing Multiple Sclerosis 55 Diabetes Complications 55 Breast Cancer Detection 55 Preclinical Study 55 clinically localized prostate 55 Pharmacogenetic 55 Genital Herpes 55 WHI 55 Eye Disease 55 ILLUMINATE 55 BRAF mutated 55 Meta Analysis 55 FDA defined valvulopathy 55 randomized crossover 55 Newly Diagnosed Multiple Myeloma 55 nonfatal MI 55 Arch Neurol 55 biochemical recurrence 55 RECIST Response Evaluation Criteria 55 Prostate Specific Antigen 55 ALTTO 55 Cardiovascular Risk Factors 55 PARTNER Trial 55 Perifosine KRX 55 Nutrition Examination Surveys NHANES 55 Cochrane reviewers 55 PFO migraine 55 elevated LDL cholesterol 55 post menopausal 55 Betaferon ® 55 Acetonide 55 Chicago Multidisciplinary Symposium 55 relapsing remitting MS RRMS 55 chemoprevention trials 55 Metastatic Prostate Cancer 55 Systolic Hypertension 55 Current Controlled Trials 55 mg administered orally 55 Phase III Clinical Trial 55 Epidemiologic studies 55 Artery Disease 55 ZD# [001] 55 sunitinib malate 55 canakinumab 55 Lung Cancer Patients 55 fluvastatin 55 FDG-PET/CT 55 Pharmacokinetic 55 Coronary Artery Risk 55 Leukemias 55 Coronary Revascularization 55 serum leptin 55 plus progestin 55 Ranolazine 55 Lp PLA 2 55 Initiated Phase 55 cerebral microbleeds 55 Demonstrates Efficacy 55 gallstone disease 55 Clinicaltrials.gov 55 multicenter Phase II 55 NAMCS 55 lobular breast cancer 55 designated HVTN 55 multicentre randomized double 55 postmenopausal breast cancer 55 Nutrition Examination 55 atazanavir ritonavir 55 underwent surgical resection 55 Phase III ThermoDox 55 extracolonic findings 55 BEXXAR Therapeutic Regimen 55 Subgroup Analysis 55 chronic prostatitis 55 Postmenopausal Hormone Therapy 55 serum GGT 55 ON #.Na 55 Solid Tumors 55 Follicular Lymphoma 55 CUSTOM II 55 Alzheimer Disease Cooperative 54 Advanced Prostate Cancer 54 recurrent metastatic 54 Response Evaluation Criteria 54 Heterozygous Familial Hypercholesterolemia 54 Serious Adverse Events 54 Pivotal Clinical Trial 54 Decompensated Heart Failure 54 NCI Cancer 54 Heart Failure Trial 54 Randomized trials 54 serum IGF 54 rosuvastatin 54 atypical ductal hyperplasia 54 periprocedural MI 54 differentiated thyroid 54 observational cohort study 54 evaluating mipomersen 54 ImmuKnow assay 54 conditional logistic regression 54 bevacizumab Avastin 54 Tiotropium 54 ibandronate 54 Hepatocellular Carcinoma 54 Fixed Dose 54 Deforolimus 54 intravenous bisphosphonates 54 NCI Surveillance Epidemiology 54 Clinical Outcome 54 seminoma 54 cediranib 54 Sequenced Treatment Alternatives 54 Bladder Cancer 54 castration resistant prostate cancer 54 Bone Mineral Density 54 evaluating tivozanib 54 Cloretazine 54 Left Ventricular Dysfunction 54 Kaplan Meier method 54 factorial design 54 DSMB 54 Genetic Variation 54 Parathyroid Hormone 54 VICTOR E1 54 REACH Registry 54 strontium ranelate 54 hydroxyvitamin D levels 54 clinicaltrials.gov 54 TDF FTC 54 PRESEPT 54 ConclusionThis 54 rFVIIa 54 randomized controlled Phase 54 mITT population 54 Hormone Receptor Positive 54 ORAL Sync 54 Prolongs Survival 54 ginkgo biloba extract 54 familial aggregation 54 journal Ophthalmology 54 APTIVUS r 54 serum PSA 54 Colorectal Screening 54 Phase IIb III 54 Zoledronic Acid 54 Study HERS 54 pharmacokinetic characteristics 54 lumiracoxib 54 abiraterone 54 Nephrology Dialysis Transplantation 54 HIV seronegative 54 DCCT 54 INCB# [003] 54 CIMZIA TM certolizumab pegol 54 postmenopausal osteoporotic women 54 randomized clinical trials 54 ertapenem 54 nondiabetic patients 54 ADVANCE PD 54 EOquin TM 54 ARCOXIA 54 p# biomarker 54 undergone hysterectomies 54 Gynecological Cancer 54 ICON7 54 Hospitals Leuven Belgium 54 Coronary Artery Bypass Graft 54 chromium supplementation 54 ATAC Arimidex Tamoxifen Alone 54 COPAXONE R 54 Heart Failure Patients 54 KRAS mutations occur 54 EQUIP OB 54 Computed Tomographic 54 meta analysis pooling 54 controlled multicenter 54 Treating Chronic 54 prelicensure 54 Aromatase Inhibitors 54 Randomized Comparison 54 journal Urology 54 EBUS FNA 54 prospectively stratified 54 Memory Study WHIMS 54 Dr. Kandzari 54 Aggressive Drug Evaluation 54 prospective multicenter randomized 54 EXPLORE Xa 54 lipid lowering therapy 54 subclinical hypothyroidism 54 Unstable Angina 54 endometrial carcinoma 54 Normative Aging Study 54 secondary efficacy endpoints 54 CHARISMA trial 54 TAXUS V 54 XL# SAR# 54 Genitourinary Cancers Symposium 54 Male Infertility 54 Truvada tablets 54 ASCUS 54 preoperative chemotherapy 54 tipranavir ritonavir 54 phase Ib 54 CLARITY study 54 MERIT ES 54 enzastaurin 54 SCIg 54 Myocardial Ischemia 54 anastrazole 54 cutaneous squamous cell carcinoma 54 Second Pivotal Phase 54 treatment naive genotype 54 Cervical Dysplasia 54 visceral metastases 54 Localized Prostate Cancer 54 tumor recurrence 54 Non Alcoholic Steatohepatitis 54 HPV-#/# 54 ductal carcinomas 54 Study ARIC 54 oral FTY# 54 biliary tract cancer 54 ACS NSQIP 54 Acute Heart Failure 54 PREZISTA r 54 candesartan 54 Dose escalation 54 Proves Effective 54 Major Adverse Cardiac 54 DBMD 54 finasteride Proscar 54 Lawrencia Bembenek Story 54 PRADAXA 54 Safinamide 54 Brentuximab Vedotin SGN 54 Fracture Risk 54 Acute Liver Failure 54 VICTOR E3 54 resected pancreatic cancer 54 NHANES #-# 54 prognostic variables 54 rosuvastatin Crestor 54 recurrent ovarian cancer 54 APTIVUS 54 adjuvant radiation 54 Watchful Waiting 54 Randomized Controlled Trial 54 Dasatinib 54 placebo controlled clinical trials 54 Stop Hypertension DASH 54 randomized placebo controlled 54 #q# deletion syndrome 54 Advanced Renal Cell 54 premenopausal women 54 Prostate Screening 54 prospective randomized controlled 54 oral deforolimus 54 Genetic Markers 54 PANVAC VF 54 octreotide LAR 54 Prostate Specific Antigen PSA 54 Genes Predict 54 RCW breast cancer 54 Cholesterol Levels 54 BJU International 54 ClinicalTrials.gov Identifier NCT# 54 Diabetic Retinopathy 54 everolimus eluting stent 54 colorectal adenomas 54 Peptide YY 54 mg/m2 dose 54 valvulopathy 54 cancer mCRC 54 dose escalation clinical 54 crizotinib PF # 54 cluster randomized controlled 54 nonmetastatic prostate cancer 54 Etanercept 54 Observational Study 54 NLSY 54 Statistically Significant 54 Medical Expenditure Panel 54 tibolone 54 placebo controlled multicenter 54 rosuvastatin #mg 54 Uterine Fibroids 54 ABSORB trial 54 Myocardial Infarction Study 54 Antifungals 54 Aflibercept 54 Cancer Incidence 54 LEXIVA r 54 Nutritional Examination Survey 54 CVD mortality 54 hormone therapy estrogen 54 PD2i ® 54 Diabetic Macular Edema 54 NATRECOR ® 54 HER2 overexpression 54 Bowel Project NSABP 54 neratinib 53 virologic failures 53 Ovarian Cancer Patients 53 Rosuvastatin 53 serum estradiol 53 follicular lymphomas 53 Prostate Cancer Survival 53 VaD 53 DEXA scan 53 Mylotarg 53 Femara letrozole 53 TIMI Study Group 53 IMPACT DCM 53 ximelagatran 53 patients evaluable 53 Hormone Therapy 53 Neuradiab TM 53 placebo controlled 53 bepotastine besilate nasal spray 53 Prehypertension 53 subclinical atherosclerosis 53 retrospective observational study 53 peritoneal cancer 53 Hemodialysis Patients 53 ascending dose 53 medulloblastomas 53 Endovascular Valve Edge 53 pancreatic adenocarcinoma 53 BRCA2 mutation carriers 53 microalbumin 53 Ischemic 53 tolvaptan 53 prostate specific antigen 53 undergoing radical prostatectomy 53 beta blocker therapy 53 Phase IIB 53 COR Diabetes 53 KRAS variant 53 Ischemic Heart Disease 53 evaluable patients 53 journal Transfusion